ASCO 2023 – Jennifer Elliott
Some of the most impactful news out of ASCO 2023 dealt with new treatments for patients with few options in the status quo of cancer care.
Jennifer Elliott, global solid tumour lead at Takeda, spoke with pharmaphorum editor-in-chief Jonah Comstock about the company’s Fruquintinib product in late-stage metastatic colorectal cancer, in-licensed from HUTCHMED, and how it could provide new hope for patients with few options.
At ASCO, Takeda was sharing not just new efficacy data, which showed an increase in overall survival against placebo and best supportive care, but also news that the product was granted priority review from the US FDA.
They also discuss some of the other major trends at the show, the potential of AI in personalised medicine, and the importance of not leaving patients behind with too myopic a focus on targeted therapies. Check out the whole interview below.
